提醒专家通道今日巴克莱主办RDN/HTN专家电话会议- RDN在高血压治疗中的初步应用及机会，以及HTN治疗学的创新

Event DescriptionWe are hosting a conference call with Dr. Randall Zusman, Director of the Division ofHypertension at Mass General to discuss the initial adoption and potential scope oftreatment for renal denervation (MDT's Symplicity and Recor’s Paradise) in patients withdrug-resistant hypertension. We expect potential implications for OW-rated MDT and BSX,and for OTSKF (Otsuka, not covered). We hope you can join us!Companies in Focus:OW-rated MDT, BSX. Also relevant for OTSKF (not covered)Meet the SpeakerDr. Randall Zusman is a Cardiologist and the Director of the Division of Hypertension atMassachusetts General Hospital in Boston. He is also an Associate Professor of Medicine atHarvard Medical School. Dr. Zusman has published extensively on hypertension and isboard-certified in internal medicine and cardiovascular disease.Meet the Analysts Matt Miksic joined Barclays in July 2022 with over 20 yearsof experience covering U.S. Medical Supplies and Devices.Matt previously covered Med Tech at Morgan Stanley,PiperJaffray,UBS and most recently at Credit Suisse. Priorto covering Med Tech, Matt was a member of the MorganStanley EnterpriseSoftwareresearch team, and prior tojoining Morgan Stanley was a senior manager with ArthurAndersen in its business consulting division and spent fiveyears with asoftwarestart-up. Matt holds a B.A. incomputer science from Rutgers University and an M.B.A.from the Leonard N. Stern School of Business at New YorkUniversity.View Analyst PageEmily Field is a Director and Head of the EuropeanPharmaceuticals team at Barclays. Ms. Field joinedBarclays and moved to London in December 2017, prior towhich she spent her career on the buy side in New YorkCity. Ms. Field worked at investment funds (including UBSO’Connor and Millennium Management) under variousstrategies, including Risk Arbitrage and Equity Long/Short.She has focused on fundamental analysis of thehealthcare/pharmaceutical sector for nearly 15 years. Shedouble majored in Economics and History at YaleUniversity and is also a CFA Charterholder. Ms. Field isoriginally from Chicago, Illinois.View Analyst Page Matt Miksic+1 212 526 9189BCI, USCaroline Council+1 212 526 9046BCI, USEmily Field, CFA+44 (0)20 7773 6263Barclays, UKU.S. Medical Supplies & DevicesEuropean Pharmaceuticals & Life SciencesThis event is intended for Barclays institutional investor clients only. This event is strictly and solelyfor the benefit of the intended recipients. Please do not forward this invitation to any other partywithout written consent from Barclays Research. Barclays' Investment Bankers are permitted toattend this event. Participant comments are not for attribution.If your firm is in-scope for research unbundling under MiFID II and you require further informationregarding pricing to participate in this Barclays Research content event, please contact your salesrepresentative.Barclays Events Terms of Service | Barclays Events Privacy NoticeDisclaimer:BARCLAYSThis communication has been prepared by Barclays.“Barclays” means any entity within the Barclays Group of companies, where “Barclays Group” meansBarclays Bank PLC, Barclays PLC and any of their subsidiaries,affiliates,ultimate holding companyand any subsidiaries oraffiliatesof such holding company.CONFLICTS OF INTERESTBARCLAYS IS A FULL SERVICE INVESTMENT BANK. In the normal course ofofferinginvestment bankingproducts and services to clients, Barclays may act in several capacities (including issuer, marketmaker and/or liquidity provider, underwriter, distributor, index sponsor, swap counterparty andcalculation agent) simultaneously with respect to a product, giving rise to potential conflicts ofinterest which may impact the performance of a product.BARCLAYS POSITIONSBarclays may at any time acquire, hold or dispose of long or short positions (including hedging andtrading positions) and trade or otherwiseeffecttransactions for their own account or the account oftheir customers in the products referred to herein which may impact the performance of a product.FOR INFORMATION ONLYTHIS DOCUMENT IS PROVIDED FOR INFORMATION PURPOSES ONLY AND IT IS SUBJECT TO CHANGE.This information has been prepared by the Research Department within the Investment Bank ofBarclays. The information, analytic tools, and/or models referenced herein (and any reports or resultsderived from their use) are intended for informational purposes only. Barclays has no obligation toupdate this information and may cease provision of this information at any time and without notice.NO OFFERBarclays is notofferingto sell or seekingoffersto buy any product or enter into any transaction. Anyofferor entry into any transaction requires Barclays’ subsequent formal agreement which will besubject to internal approvals and execution of binding transaction documents. The products William McMahon+1 212 526 3816BCI, US mentioned may not be eligible for sale in some states or countries, nor suitable for all types ofinvestors. Without limitation t